Madrigal Pharmaceuticals (MDGL) Competitors

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.

Does the MarketBeat Community favor DRNA or MDGL?

Dicerna Pharmaceuticals received 2 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. However, 68.17% of users gave Madrigal Pharmaceuticals an outperform vote while only 62.28% of users gave Dicerna Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Dicerna Pharmaceuticals	Outperform Votes 454 62.28%	Underperform Votes 275 37.72%
Madrigal Pharmaceuticals	Outperform Votes 452 68.17%	Underperform Votes 211 31.83%

Which has more risk & volatility, DRNA or MDGL?

Dicerna Pharmaceuticals has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.42, meaning that its share price is 142% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in DRNA or MDGL?

78.9% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 10.2% of Dicerna Pharmaceuticals shares are owned by insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has better valuation and earnings, DRNA or MDGL?

Dicerna Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dicerna Pharmaceuticals	$164.31M	18.17	-$112.75M	-$1.63	-23.45
Madrigal Pharmaceuticals	N/A	N/A	-$373.63M	-$23.09	-12.32

Do analysts rate DRNA or MDGL?

Madrigal Pharmaceuticals has a consensus price target of $348.50, suggesting a potential upside of 22.50%. Given Dicerna Pharmaceuticals' higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Dicerna Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dicerna Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Is DRNA or MDGL more profitable?

Madrigal Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -64.53%. Madrigal Pharmaceuticals' return on equity of -103.08% beat Dicerna Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dicerna Pharmaceuticals	-64.53%	-103.08%	-16.58%
Madrigal Pharmaceuticals	N/A	-128.60%	-78.52%

Does the media prefer DRNA or MDGL?

In the previous week, Madrigal Pharmaceuticals had 8 more articles in the media than Dicerna Pharmaceuticals. MarketBeat recorded 8 mentions for Madrigal Pharmaceuticals and 0 mentions for Dicerna Pharmaceuticals. Dicerna Pharmaceuticals' average media sentiment score of 0.45 beat Madrigal Pharmaceuticals' score of 0.00 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Dicerna Pharmaceuticals	Neutral
Madrigal Pharmaceuticals	Neutral

Summary

Madrigal Pharmaceuticals beats Dicerna Pharmaceuticals on 9 of the 16 factors compared between the two stocks.